DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.
Several other analysts have also recently weighed in on the company. Zacks Investment Research cut DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a report on Wednesday. Bank of America dropped their price target on DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 2nd. Stifel Nicolaus assumed coverage on DBV TECHNOLOGIE/S in a research note on Thursday, September 13th. They set a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley lowered their price objective on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 11th. Finally, ValuEngine upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. DBV TECHNOLOGIE/S has a consensus rating of “Buy” and an average target price of $33.67.
NASDAQ:DBVT opened at $20.00 on Friday. DBV TECHNOLOGIE/S has a 1-year low of $16.65 and a 1-year high of $26.98.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.